Download Previous Appointments

CURRICULUM VITAE
Name:
Gerald Angus James McIndoe
Date of Birth:
24 August 1955
Address:
Department of Obstetrics and Gynaecology
Hammersmith Hospital
Du Cane Road
London W12 0HS
Telephone:
+44 (0)20 8383 3268
Fax:
+44 (0)20 8383 8065
Present Appointment:
Consultant in Gynaecological Oncology
Hammersmith Hospitals NHS Trust
RCOG Accreditation:
General accreditation in
Obstetrics and Gynaecology
Subspecialist accreditation in
Gynaecological Oncology
Qualifications:
Societies:
BSc Auckland
1974
MB ChB Auckland
1980
FRCS England
1985
MRCOG London
1987
PhD London
1993
British Medical Association
British Society for Colposcopy and Cervical Pathology
British Gynaecological Cancer Society
Royal Society of Medicine
PREVIOUS APPOINTMENTS
Saint Mary's Hospital - Addenbrooke's Hospital Senior Registrar Rotation
Jan 1993 - Oct 1994
Senior Registrar in Obstetrics
and Gynaecology
Addenbrooke's NHS Trust
Rosie Maternity Hospital,
Cambridge
Jan 1991 - Dec 1992
RCOG approved Subspecialty
Trainee in Gynaecological Oncology
Hammersmith Hospital
London and
St Mary's Hospital
London
Clinical Research Fellow
(Prof PCL Beverley)
Human Tumour
Immunology Group,
Imperial Cancer Research
Fund, London
May 1987 - March 1988
Registrar in Obstetrics and
Gynaecology
St Mary's Hospital
London
July 1985 - Dec 1986
Registrar in Obstetrics and
Gynaecology (Rotating position)
National Women's Hospital
Auckland, New Zealand
June 1982 - May 1983
SHO in Obstetrics and Gynaecology
Whittington Hospital
London
Jan 1984 - June 1985
Registrar in General Surgery
(Mr BL Dowling)
Northampton General
Hospital, Northampton
Aug 1983 - Jan 1984
SHO in General Surgery
(Miss AO Mansfield)
Royal Postgraduate
Medical School
Hammersmith Hospital
London
House Officer
Cook Hospital
Gisborne, New Zealand
Research Training
April 1988 - Dec 1990
Obstetrics and Gynaecology
General Surgery
Pre-registration Training
Dec 1980 - Nov 1981
PhD Thesis: Cell mediated immune response to HPV 16
I was employed on a clinical research fellowship by the Imperial Cancer Research Fund.
Under Professor Peter Beverley, I investigated the role of the cellular immune system in
modulating the natural history of human papillomavirus (HPV) infection and neoplasia of the
cervix. This work has been accepted as a PhD by the University of London.
Initial experiments used synthetic peptides from the L1 and E6 open reading frames (ORFs)
of HPV 16, identified on the basis of the Rothbard and Taylor predictive algorithm, as
antigen in studies of proliferation of PBMC to HPV antigens. DR restriction of these peptide
determinants was mapped using transfected L cells, and homologous peptides from other
HPV types were tested for their ability to stimulate PBMC and T cell lines. These peptides
were used to assay proliferative responses in patients with premalignant and malignant
disease associated with HPV 16. Preliminary results suggested that patients with advanced
disease responded more strongly to these antigens.
To identify cytotoxic T lymphocytes (CTL) directed against HPV 16 antigens, cells
expressing HPV 16 proteins and appropriate MHC molecules are required. The traditional
approach is to use autologous antigen presenting cells infected with the virus, but since
infectious virus is not available, a variety of alternative stimulators were generated using
molecular biological techniques. These included murine tumour cell lines expressing
transfected HLA genes and HPV ORFs, recombinant HPV-vaccinia virus constructs to infect
autologous antigen presenting cells, and established cervical tumour cell lines with HLA
matched donors. For a variety of different reasons, none of these approaches were successful.
As an alternative approach, keratinocytes were tested for their ability to present antigen to
both class I and class II restricted T cells. Antigen was presented poorly to class I restricted T
cells but keratinocytes expressing class II were unable to induce proliferation of an influenza
HA-specific, DR4 restricted human T cell clone. Co-culture of the clone with HA peptide and
IFN  treated keratinocytes did not simply fail to cause T cell proliferation, rather a state of
anergy resulted whose induction was antigen specific and DR restricted.
Because of the difficulties in identifying human CTL responses, a mouse model was
developed with a view to returning to the human system when suitable stimulators had been
identified. In this model, HPV 16 L1 and E7 specific CTL were identified, and the
determinants were mapped using synthetic peptides. Recombinant vaccinia virus constructs
expressing L1 and E7 were shown to prime HPV 16 specific CTL in the mouse, and were
also shown to boost CTL responses in vitro. These constructs are likely to be suitable as
stimulators of human CTL.
PUBLICATIONS
deSouza NM, Dina R, McIndoe GA, Soutter WP. Cervical cancer: value of an endovaginal
coil magnetic resonance imaging technique in detecting small volume disease and assessing
parametrial extension. Gynecol Oncol. 2006; 102: 80-5.
Saini A, Dina R, McIndoe GA, Soutter WP, Gishen P, deSouza NM. Characterization of
adnexal masses with MRI. Am J Roentgenol 2005; 184: 1004-9.
deSouza NM, O'Neill R, McIndoe GA, Dina R, Soutter WP. Borderline tumors of the ovary:
CT and MRI features and tumor markers in differentiation from stage I disease. Am J
Roentgenol 2005; 184: 999-1003.
Mahon MM, deSouza NM, Dina R, Soutter WP, McIndoe GA, Williams AD, Cox IJ.
Preinvasive and invasive cervical cancer: an ex vivo proton magic angle spinning magnetic
resonance spectroscopy study. NMR Biomed 2004; 17: 144-53.
Nicholson S, Bomphray CC, Thomas H, McIndoe A, Barton D, Gore M, George AJT. A
phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer. Cancer Immunol
Immunother 2004; 53: 809-16.
SoutterWP, Hanoch J, D'Arcy T, Dina R, McIndoe GA, deSouza NM. Pre-treatment tumour
volume measurement on high-resolution magnetic resonance imaging as a predictor of
survival in cervical cancer. BJOG 2004; 111: 741-7.
Mahon MM, Cox IJ, Dina R, Soutter WP, McIndoe GA, Williams AD, deSouza NM. 1H
Magnetic Resonance Spectroscopy of preinvasive and invasive cervical cancer: in vivo - ex
vivo profiles and effect of tumor load. JMRI 2004; 19: 35-64.
deSouza NM, Soutter WP, Rustin G, Mahon MM, Jones B, Dina R, McIndoe GA. Use of
neoadjuvant chemotherapy prior to radical hysterectomy in cervical cancer: monitoring
tumour shrinkage and molecular profile on magnetic resonance and assessment of 3-year
outcome. Br J Cancer 2004; 90: 2326-31.
Diac M, Hanoch J, McIndoe A, Dina R. Keratin induced granulomatous disease of the vagina
mimicking a malignant tumour. BJOG 2004; 111: 389-90.
Mahon MM, Williams AD, Soutter WP, Cox IJ, McIndoe GA, Coutts GA, Dina R, deSouza
NM. 1H Magnetic Resonance Spectroscopy of invasive cervical cancer: an in vivo study with
ex vivo corroboration. NMR in Biomedicine 2004; 17: 1-9.
Connors A, deSouza NM , McIndoe GA. Adenomyoma mimicking an aggressive uterine
neoplasm on MRI. Br J Radiol 2003; 76: 66-68.
Gornall RJ, Standfield N, deSouza NM, Aachi VR, McIndoe GA. Resection of recurrent
bulky gynaecological side wall malignancy with iliac vessel reconstruction. BJOG 2001; 108:
1305-8.
Soutter WP, Haidopoulos D, Gornall RJ, McIndoe GA, Fox J, Mason WP, Flanagan A,
Nicholas N, Barker F, Abrahams J, Lampert I, Sarhanis P. Is conservative treatment for
adenocarcinoma in situ of the cervix safe? BJOG 2001; 108: 1184-9.
Williams AD, Cousins C, Soutter WP, Mubashar M, Peters AM, Dina R, Fuchsel F, McIndoe
GA, deSouza NM. Detection of pelvic lymph node metastases in gynecologic malignancy: a
comparison of CT, MR imaging, and positron emission tomography. Am J Roentgenol 2001;
177: 343-8.
deSouza NM, Whittle M, Williams AD, Sohail M, Krausz T, Gilderdale DJ, McIndoe GA,
Soutter WP. Magnetic resonance imaging of the primary site in stage I cervical carcinoma: A
comparison of endovaginal coil with external phased array coil techniques at 0.5T. Journal of
Magnetic Resonance Imaging. 2000; 12: 1020-6.
D'Arcy TJ, Roy A, Thomas A, McIndoe A, Soutter WP. Standards for the management of
cervical and vulval carcinoma. British Journal of Obstetrics & Gynaecology 2000; 107: 8468.
Panoskaltsis TA, Moore DA, Haidopoulos DA, McIndoe AG. Tuberculous peritonitis: part of
the differential diagnosis in ovarian cancer. Am J Obstet Gynecol 2000; 182: 740-2.
Basu PS, D’Arcy T, McIndoe A, Soutter WP. Is needle diathermy excision of the
transformation zone a better treatment for cervical intraepithelial neoplasia than large loop
excision? Lancet 1999; 353: 1852-3.
deSouza NM, McIndoe GA, Soutter WP, Krausz T, Chui KM, Hughes C, Mason WP. Value
of magnetic resonance imaging with an endovaginal receiver coil in the pre-operative
assessment of Stage I and IIa cervical neoplasia. British Journal of Obstetrics & Gynaecology.
1998; 105: 500-7.
deSouza NM, Soutter WP, McIndoe GA, Gilderdale DJ, Krausz T. Stage I cervical cancer:
tumor volume by magnetic resonance imaging of screen-detected versus symptomatic lesions.
Journal of the National Cancer Institute. 1997; 89: 1314-5.
Tarpey I, Stacey SN, McIndoe A, Davies DH. Priming in vivo and quantification in vitro of
class I MHC-restricted cytotoxic T cells to human papilloma virus type 11 early proteins (E6
and E7) using immunostimulating complexes (ISCOMs). Vaccine 1996; 14: 230-6.
Tarpey I, Stacey S, Hickling J, Birley HDL, Renton A, McIndoe A, Davies DH. Human
cytotoxic T lymphocytes stimulated by endogenously processed human papillomavirus type
11 E7 recognize a peptide containing a HLA-A2 (A*0201) motif. Immunol. 1994; 81: 222-7.
Davies DH, Tarpey I, Stacey S, Hickling J, Bartholomew J, Birley H, Renton A, McIndoe A.
Human cytotoxic T cell epitopes in HPV 11: relationships between allele-specific motifs,
HLA binding, and stimulation in vitro. Proceedings of the 2nd Intl. Wrkshp of Immunol. of
HPV Infections, Cambridge June 1993.
Yahya AA. McIndoe GA. Mason WP. Analysis and outcome of 502 cases of laser excision
cone (LEC) at the Samaritan Hospital for Women, London. Asia-Oceania J Obstet Gynaecol
1992; 18: 315-8.
Zhou J, McIndoe GAJ, Davies HD, Sun X-Y, Crawford L. The induction of cytotoxic T cells
by recombinant vaccinia viruses expressing human papillomavirus type 16 L1.
Virol 1991; 181: 203-10.
Davies HD, McIndoe GAJ, Chain BM: Cancer of the cervix: prospects for immunological
control. Br J Exp Pathol 1991; 72: 239-51.
Dent CL. McIndoe GA. Latchman DS. The constitutively expressed octamer binding protein
OTF-1 and a novel octamer binding protein expressed specifically in cervical cells bind to an
octamer-related sequence in the human papillomavirus 16 enhancer. Nucleic Acids Research.
1991; 19: 4531-5.
Bal V, McIndoe A, Denton G, Hudson D, Lombardi G, Lamb J and Lechler R: Antigen
presentation by keratinocytes induces tolerance in human T cells. Eur J Immunol 1990; 20:
1893-7.
Strang G, Hickling JK, McIndoe GAJ, Howland K, Wilkinson D, Ikeda H and
Rothbard JB: Human T cell responses to human papillomavirus type 16 L1 and E6 synthetic
peptides: Identification of T cell determinants, HLA-DR restriction and virus type specificity.
J Gen Virol 1990; 71: 423-31.
Greco A, Mason P, Leung AWL, Dische S, McIndoe GAJ and Anderson MC: Staging of
carcinoma of the uterine cervix: MRI - surgical correlation. Clin Radiol 1989; 40: 401-5.
McIndoe GAJ, Smith R, Tidy JA, Yayah A, Mason WP, Anderson MC: Occult cervical
carcinoma revealed by large loop diathermy. Lancet 1989; ii: 807.
McIndoe GAJ, Robson MS, Tidy JA, Mason WP and Anderson MC: Laser excision rather
than vaporization: the treatment of choice for cervical intraepithelial neoplasia. Obstet
Gynecol 1989; 74: 165-8.
McIndoe GAJ, Jones RW and Grieve B: The Aldridge sling procedure in the treatment of
urinary stress incontinence. Aust NZ J Obstet Gynaecol 1987; 27: 238-9.
Salem RR, McIndoe GAJ, Matkin JA, Lidou ACM and Wood CB: The haematologic effects
of Latamoxef Sodium when used as a prophylaxis during surgical treatment. Surg Obstet
Gynecol 1987; 164: 525-9.
McIndoe GAJ and Hopkins NFG: "Spontaneous" rupture of the diaphragm.
Postgrad Med J 1986; 62: 389-91.
McIndoe GAJ, Menzies KW and Reddy J: Sulindac (Clinoril) and cholestatic jaundice.
NZ Med J1981; 94: 430-1.